MAT Tools and Resources

This web page is a resource center for social media, video, print, radio, FAQs, messaging, and other marketing materials that can be used to promote the 988 Suicide & Crisis Lifeline. It is designed for states, territories, tribes, crisis centers, communities, emergency service providers, and other partners to speak with one voice.

This guideline provide evidence-based strategies and standards of care for the treatment of stimulant use disorders, stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use.

This toolkit is a resource for Peer Recovery Specialists (PRSs) to feel equipped to discuss MOUD with providers, people seeking recovery, and others with questions about this treatment option.

This SAMHSA Advisory outlines the principles and components of low barrier care and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research.

This virtual public meeting which explored real-world experiences and scientific evidence for buprenorphine initiation strategies, as well as medication dosing and management during continued treatment across different care settings

This issue brief provides federal and state policymakers with ways they can support low-threshold buprenorphine prescribing through reimbursement policies, treatment guidelines, and regulations.

This report, produced in collaboration with the Partnership to End Addiction, analyzes standards of prior authorization requirements in both public and private insurance plans.

This fact sheet provides guidance for patients starting buprenorphine outside of hospitals or clinics.

These guidelines provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.